Phase 2 N=144 Olanzapine for Nausea After Surgery
Postoperative Nausea and Vomiting
Primary: Number of Participants With Nausea and/or Vomiting — 10; 26 Participants — p=0.003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=180 Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients
Postoperative Nausea and Vomiting
Primary: Incidence of Postoperative Nausea and Vomiting — 34.4; 29.8; 12.5; 7 percentage of participants — p=>0.76
Phase 4 N=54 Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis
Postoperative Nausea and Vomiting
Primary: PONV Incidence — 12 participants
N/A N=27,034 Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
Postoperative Nausea and Vomiting
Primary: Adherence to PONV Guidelines — 666; 5260; 5863 Participants
Phase 4 N=141 Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting
Post-operative Nausea and Vomiting
Primary: Nausea Scale — 3.5; 4.0; 4.0; 2.0 score on a scale
N/A N=115 Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
Nausea · Vomiting
Primary: Number of Participants With Nausea and Vomiting — 24; 29 participants
N/A N=115 Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
Nausea · Vomiting
Primary: Number of Participants With Postoperative Nausea and Vomiting — 28; 34 participants
N/A N=200 Aprepitant for Post-operative Nausea
Postoperative Nausea
Primary: Post-operative Nausea and Vomiting
Phase 4 N=83 Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
Post-operative Nausea and Vomiting · Laparoscopic Sleeve Gastrectomy
Primary: Number of Participants With PONV-related Delay of Hospital Discharge — 0; 4 Participants
Phase 4 N=92 Pharmacogenomics and Post-Operative Nausea and Vomiting
Postoperative Nausea
Primary: Episodes of Postoperative Nausea — 0; 16 episodes
Phase 4 N=124 Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery
Postoperative Nausea and Vomiting
Primary: PONV During the First 24 Hours After Bariatric Surgery — 22; 12 participants — p=0.04
Phase 4 N=98 Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy
Nausea and Vomiting, Postoperative
Primary: Incidence of Nausea — 46; 54 percentage of participants
Phase 4 N=150 Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery
Postoperative Nausea and Vomiting
Primary: Number of Participants Having Post-operative Emesis and Nausea. — 7; 22 participants — p=<0.05
Phase 2 N=257 Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)
Postoperative Nausea and Vomiting
Primary: Experienced Post-operative Nausea or Vomiting — 25; 29; 20; 30 participants
Phase 4 N=121 Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
Postoperative Nausea and Vomiting (PONV) · Nausea
Primary: Proportion of Patients With a Complete Response/Complete Control During the First 24 Hours After Neurological Surgery Under General Anesthesia — 38; 41; 30; 30…
Phase 3 N=670 Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
Postoperative Nausea and Vomiting
Primary: Proportion of Patients With Complete Response — 78.2; 82.7 percentage of patients
Phase 4 N=115 Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
Postoperative Nausea and Vomiting
Primary: Cumulative Incidence of Emesis — 8; 20 participants
N/A N=160 Effect of Intraoperative Crystalloid Volume on Postoperative Vomiting
Postoperative Vomiting
Primary: Postoperative Vomiting — 11; 9; 66; 68 participants — p=0.05
Phase 3 N=1,147 Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
PONV
Primary: Number of Participants With Complete Response — 330; 268 Participants — p=<0.001
Phase 2 N=50 Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting
Postoperative Nausea and Vomiting
Primary: Number of Participants With Complete Response (CR), No PONV Symptoms, Nausea — 8; 25; 24; 28 Participants
N/A N=88 Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
Postoperative Nausea and Vomiting
Primary: The Incidence of Postoperative Nausea and Vomiting — 5; 18 Participants — p=<0.05
Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
Phase 3 N=150 Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
Postoperative Nausea and Vomiting
Primary: Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively — 88.0; 84.0 percentage of patients
Phase 2 N=215 Phase II Dose-ranging Study of APD421 in PONV
Postoperative Nausea and Vomiting
Primary: Post-operative Nausea or Vomiting — 37; 28; 20; 30 participants
N/A N=84 Guanfacine for PONV and Pain After Sinus Surgery
Postoperative Nausea and Vomiting · Pain, Postoperative
Primary: Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) — 35; 33; 1; 2 Participants
Phase 3 N=216 A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)
Post-Operative Nausea and Vomiting
Primary: Number of Patients With Clinical Adverse Experiences (CAEs) — 125; 32 Participants
N/A N=306 Prevention of Intraoperative Nausea and Vomiting During Cesarean Section
Cesarean Delivery
Primary: Intraoperative Nausea and Vomiting — 23; 31; 49 participants
N/A N=150 Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients
Gynecological Disease
Primary: Incidence of Postoperative Nausea and Vomiting — 21; 11; 10 participants
Phase 2 N=228 A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)
Post-operative Nausea · Post-operative Vomiting
Primary: Area Under the Concentration-time Curve of Aprepitant From Time 0 to the Last Measurable Concentration (AUC0-last) Following Administration of 125 mg Dose Equivalent in…
Phase 2 N=220 Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)
Postoperative Nausea and Vomiting
Primary: Percentage of Participants With Complete Control — 25.0; 18.0 percentage of participants — p=0.4010